Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel; Gary J. Schiller; Christy J. Samaras; Michael Sebag; Jesus G. Berdeja; Siddhartha Ganguly; Jeffrey V. Matous; Kevin W Song; Christopher S. Seet; Mirelis Acosta-Rivera; Michael Bar; Donald P. Quick; Bertrand M. Anz; Gustavo A. Fonseca; Donna E. Reece; Kim Lee; Weiyuan Chung; Amit Agarwal; Nizar J. Bahlis

doi:10.1182/BLOOD-2020-134189

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel
, Gary J. Schiller
, Christy J. Samaras
, Michael Sebag
, Jesus G. Berdeja
, Siddhartha Ganguly
, Jeffrey V. Matous
, Kevin W Song
, Christopher S. Seet
, Mirelis Acosta-Rivera
, Michael Bar
, Donald P. Quick
, Bertrand M. Anz
, Gustavo A. Fonseca
, Donna E. Reece
, Kim Lee
, Weiyuan Chung
, Amit Agarwal
, Nizar J. Bahlis

Hackensack University Medical Center
University of California, Los Angeles
Cleveland Clinic
McGill University Health Centre
Sarah Cannon Research Institute
University of Kansas
Colorado Blood Cancer Institute, Denver, CO
Vancouver General Hospital
Fundacion de Investigacion, San Juan, Puerto Rico
Stamford Hospital
Joe Arrington Cancer Research and Treatment Center, Lubbock, TX
Tennessee Oncology, Chattanooga, TN
Florida Cancer Specialists, St Petersburg, FL
Princess Margaret Cancer Centre
Bristol-Myers Squibb
Tom Baker Cancer Center, Calgary, Canada

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-134189
State	Published - Nov 5 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1182/BLOOD-2020-134189License: Unspecified

Cite this

Siegel, D. S., Schiller, G. J., Samaras, C. J., Sebag, M., Berdeja, J. G., Ganguly, S., Matous, J. V., Song, K. W., Seet, C. S., Acosta-Rivera, M., Bar, M., Quick, D. P., Anz, B. M., Fonseca, G. A., Reece, D. E., Lee, K., Chung, W., Agarwal, A., & Bahlis, N. J. (2020). Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial. Blood, 136. https://doi.org/10.1182/BLOOD-2020-134189

Siegel, DS, Schiller, GJ, Samaras, CJ, Sebag, M, Berdeja, JG, Ganguly, S, Matous, JV, Song, KW, Seet, CS, Acosta-Rivera, M, Bar, M, Quick, DP, Anz, BM, Fonseca, GA, Reece, DE, Lee, K, Chung, W, Agarwal, A & Bahlis, NJ 2020, 'Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial', Blood, vol. 136. https://doi.org/10.1182/BLOOD-2020-134189

@article{1e95768ce4494fd58b2b55b8047c63a9,

title = "Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial",

author = "Siegel, \{David S.\} and Schiller, \{Gary J.\} and Samaras, \{Christy J.\} and Michael Sebag and Berdeja, \{Jesus G.\} and Siddhartha Ganguly and Matous, \{Jeffrey V.\} and Song, \{Kevin W\} and Seet, \{Christopher S.\} and Mirelis Acosta-Rivera and Michael Bar and Quick, \{Donald P.\} and Anz, \{Bertrand M.\} and Fonseca, \{Gustavo A.\} and Reece, \{Donna E.\} and Kim Lee and Weiyuan Chung and Amit Agarwal and Bahlis, \{Nizar J.\}",

note = "Oral and Poster Abstracts 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II Combinations, Therapies, Adverse Events, Clinically relevant David S. Siegel, MD 1, Gary J. Schiller, MD 2, Christy J. Samaras, DO 3, Michael Sebag, MD, PhD 4, Jesus G. Berdeja, MD 5, Siddhartha Ganguly, MD 6 *, Jeffrey V.",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/BLOOD-2020-134189",

language = "American English",

volume = "136",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

AU - Siegel, David S.

AU - Schiller, Gary J.

AU - Samaras, Christy J.

AU - Sebag, Michael

AU - Berdeja, Jesus G.

AU - Ganguly, Siddhartha

AU - Matous, Jeffrey V.

AU - Song, Kevin W

AU - Seet, Christopher S.

AU - Acosta-Rivera, Mirelis

AU - Bar, Michael

AU - Quick, Donald P.

AU - Anz, Bertrand M.

AU - Fonseca, Gustavo A.

AU - Reece, Donna E.

AU - Lee, Kim

AU - Chung, Weiyuan

AU - Agarwal, Amit

AU - Bahlis, Nizar J.

N1 - Oral and Poster Abstracts 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster II Combinations, Therapies, Adverse Events, Clinically relevant David S. Siegel, MD 1, Gary J. Schiller, MD 2, Christy J. Samaras, DO 3, Michael Sebag, MD, PhD 4, Jesus G. Berdeja, MD 5, Siddhartha Ganguly, MD 6 *, Jeffrey V.

PY - 2020/11/5

Y1 - 2020/11/5

UR - https://ash.confex.com/ash/2020/webprogram/Paper134189.html

U2 - 10.1182/BLOOD-2020-134189

DO - 10.1182/BLOOD-2020-134189

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Disciplines

Access to Document

Other files and links

Cite this